This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) / Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; Cheng A.-L.; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 121:7(2019), pp. 625-625. [10.1038/s41416-019-0534-2]
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)
Piscaglia F.;
2019
Abstract
This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
